anti-Coagulation Factor VIII (F8) Anticorps

F8 encodes coagulation factor VIII, which participates in the intrinsic pathway of blood coagulation\; factor VIII is a cofactor for factor IXa which, in the presence of Ca+2 and phospholipids, converts factor X to the activated form Xa. De plus, nous expédions Factor VIII Kits (62) et Factor VIII Protéines (24) et beaucoup plus de produits pour cette protéine.

afficher tous les anticorps Gène GeneID UniProt
F8 14069 Q06194
F8 2157 P00451
F8 302470  
Comment commander chez anticorps-enligne
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Commandez enligne
  • orders@anticorps-enligne.fr

Top anti-Factor VIII Anticorps sur anticorps-enligne.fr

Showing 10 out of 261 products:

Catalogue No. Reactivité Hôte Conjugué Application Images Quantité Livraison Prix Détails
Humain Lapin Inconjugué WB 100 μg 4 to 6 Days
$240.00
Détails
Boeuf (Vache) Lapin Inconjugué WB Host: Rabbit  Target Name: F8  Sample Tissue: 721_B Whole Cell  Lane A:  Primary Antibody Lane B:  Primary Antibody + Blocking Peptide Primary Antibody Concentration: 1 µg/mL Peptide Concentration: 2 µg/mL Lysate Quantity: 241 µg/laneGel Concentration: 2.12 % 100 μL 2 to 3 Days
$319.00
Détails
Chien Lapin Inconjugué WB Western blot analysis of Factor VIII expression in HeLa (A), HepG2 (B) whole cell lysates. 200 μL 13 to 14 Days
$487.50
Détails
Humain Lapin Inconjugué ELISA, ICC, IF, IHC, WB ABIN6266536 staining HuvEc cells by IF/ICC. The sample were fixed with PFA and permeabilized in 0.1% Triton X-100,then blocked in 10% serum for 45 minutes at 25°C. The primary antibody was diluted at 1/200 and incubated with the sample for 1 hour at 37°C. An Alexa Fluor 594 conjugated goat anti-rabbit IgG (H+L) antibody(Cat.# S0006), diluted at 1/600, was used as secondary antibody. Western blot analysis on HuvEc cell lysate using Factor VIII Antibody,The lane on the left is treated with the antigen-specific peptide. 100 μL 11 to 12 Days
$390.77
Détails
Humain Lapin Inconjugué ELISA, WB Western blot analysis of extracts from HuvEc cells, using Factor VIII Antibody. The lane on the right is treated with the synthesized peptide. 100 μg 2 to 3 Days
$302.50
Détails
Chien Lapin Inconjugué IF (p), IHC (p) Formalin-fixed and paraffin embedded rat tibia tissue labeled with Anti-Factor VIII (FVIII) Polyclonal Antibody (ABIN668601) , Unconjugated at 1:300, followed by conjugation to the secondary antibody and DAB staining Formalin-fixed : Mouse C57 cells labeled with Anti- Factor VIII (FVIII) Polyclonal Antibody (ABIN668601) , Unconjugated at 1:300, followed by conjugation to the secondary antibody was Goat Anti-Rabbit IgG, PE conjugated  at 1:200 for 40 minutes at 37 °C DAPI (5 µg/mL, blue) was used to stain the cell nuclei 100 μL 3 to 7 Days
$329.45
Détails
Humain Lapin Inconjugué ELISA, IHC, WB 100 μL Disponible
$363.46
Détails
Humain Lapin Inconjugué IF (p), IHC (p) Formalin-fixed and paraffin embedded human skin labeled with Anti-Factor VIII Polyclonal Antibody, Unconjugated (ABIN872493) at 1:200 followed by conjugation to the secondary antibody and DAB staining 100 μL 3 to 7 Days
$329.45
Détails
Humain Lapin Inconjugué IF (cc), IF (p), IHC (p) Formalin-fixed and paraffin embedded:human colon carcinoma labeled with Anti-factor VIII(FVIII) (human) Polyclonal Antibody (ABIN728000), Unconjugated at 1:200, followed by conjugation to the secondary antibody and DAB staining Formalin-fixed and paraffin embedded:human colon carcinoma labeled with Anti-factor VIII(FVIII)(human) Polyclonal Antibody , Unconjugated at 1:200, followed by conjugation to the secondary antibody and DAB staining 100 μL 3 to 7 Days
$329.45
Détails
Boeuf (Vache) Lapin Inconjugué WB 100 μL 11 to 14 Days
$581.17
Détails

anti-Factor VIII Anticorps mieux référencés

  1. Human Polyclonal Factor VIII Primary Antibody pour WB - ABIN3042924 : Wu, Chen, Guo, He, Hu: Effects of transforming growth factor-?2 on myocilin expression and secretion in human primary cultured trabecular meshwork cells. dans International journal of clinical and experimental pathology 2014 (PubMed)
    Show all 15 Pubmed References

  2. Human Polyclonal Factor VIII Primary Antibody pour ICC, IF - ABIN449338 : Zhu, Liu, Miao, Qu, Chi: Enhanced plasma factor VIII activity in mice via cysteine mutation using dual vectors. dans Science China. Life sciences 2012 (PubMed)
    Show all 3 Pubmed References

  3. Dog (Canine) Polyclonal Factor VIII Primary Antibody pour IF (p), IHC (p) - ABIN668601 : Yu, Zhang, Jiang, Wang, Zhang: Astragalosides promote angiogenesis via vascular endothelial growth factor and basic fibroblast growth factor in a rat model of myocardial infarction. dans Molecular medicine reports 2015 (PubMed)
    Show all 3 Pubmed References

  4. Human Polyclonal Factor VIII Primary Antibody pour IF (p), IHC (p) - ABIN872493 : Tang, Liu, Dong, Li, Li, Hou, Zheng, Lin, Ren: Protective Effect of Kaempferol on LPS plus ATP-Induced Inflammatory Response in Cardiac Fibroblasts. dans Inflammation 2014 (PubMed)
    Show all 2 Pubmed References

  5. Human Monoclonal Factor VIII Primary Antibody pour ELISA, WB - ABIN969123 : Shovlin, Sulaiman, Govani, Jackson, Begbie: Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism. dans Thrombosis and haemostasis 2007 (PubMed)
    Show all 2 Pubmed References

  6. Human Polyclonal Factor VIII Primary Antibody pour IF (cc), IF (p) - ABIN728000 : Zhou, Zhu, Zou, Wang: Changes in number and biological function of endothelial progenitor cells in hypertension disorder complicating pregnancy. dans Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 2008 (PubMed)
    Show all 2 Pubmed References

  7. Human Monoclonal Factor VIII Primary Antibody pour ELISA, WB - ABIN966113 : Venceslá, Corral-Rodríguez, Baena, Cornet, Domènech, Baiget, Fuentes-Prior, Tizzano: Identification of 31 novel mutations in the F8 gene in Spanish hemophilia A patients: structural analysis of 20 missense mutations suggests new intermolecular binding sites. dans Blood 2008 (PubMed)
    Show all 2 Pubmed References

Plus d’anticorps contre Factor VIII partenaires d’interaction

Zebrafish Coagulation Factor VIII (F8) interaction partners

  1. gene is flanked by factor VII and factor X genes; gene encodes a protein homologous to factor VII, but lacks critical residues for factor VII activity; functions as an inhibitor of blood coagulation in biochemical assays using zebrafish or human plasmas

Mouse (Murine) Coagulation Factor VIII (F8) interaction partners

  1. The increased immunogenicity of oxidized FVIII was not reverted by treatment of mice with N-acetyl cysteine, and did not implicate an increased maturation of professional antigen-presenting cells. Data document that oxidation influences the immunogenicity of therapeutic FVIII.

  2. Haemophilic animals (F8(-/-) mice) fed a high fat/fructose diet are highly prone to hepatic steatosis and thrombocytopenia.

  3. CD32 blockade suppresses the FVIII-specific recall response by two ways: i) increasing apoptosis of FVIII-specific memory B-cells and ii) disturbing FVIII-specific T cell response by modulating presentation of rhFVIII to CD4(+) T cells.

  4. Type 2N von Willebrand disease variants were associated with decreased VWF secretion and impaired factor VIII binding/stability.

  5. Cytokine release was quantified from FVIII(-/-) splenocytes restimulated with FVIII in the absence or presence of different anti-FcgammaRIIB (CD32) Antibodies (anti-CD32 mAbs) over 6 days.

  6. results revealed localized vascular expression of FVIII and von Willebrand factor and identified lymphatic endothelial cell as a major cellular source of FVIII in extrahepatic tissues.

  7. the results indicate that residues in the C1 and/or C2 domains of factor VIII are implicated in immunogenic factor VIII uptake, at least in vitro Conversely, in vivo, the binding to endogenous von Willebrand factor masks the reducing effect of mutations in the C domains on factor VIII immunogenicity.

  8. Describe a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene.

  9. data demonstrate that infusion of platelets containing FVIII triggers neither primary nor memory anti-FVIII immune response in FVIII(null) mice

  10. Both platelet-VWF and plasma-VWF are required for optimal platelet-derived FVIII gene therapy for hemophilia A in the presence of inhibitors.

  11. These data support the investigation of FVIII orthologs as treatment modalities in both the congenital and acquired FVIII inhibitor settings.

  12. Extrahepatic sources of factor VIII potentially contribute to the coagulation cascade correcting the bleeding phenotype of mice with hemophilia A.

  13. Activatable bioengineered FIX molecules with FVIII-independent activity might be a promising tool for improving hemophilia A treatment, especially for patients with inhibitors.

  14. This study demonstrated that FVIIIa interacts with Low-density lipoprotein receptor-related protein 1 cluster III.

  15. a fragment containing only approximately 20% of the VWF sequence is sufficient to support FVIII stability in vivo

  16. Endothelial cells from multiple, but not all, tissues contribute to the plasma FVIII pool in the mouse.

  17. Endothelial cells are the predominant, and possibly exclusive, source of plasma FVIII.

  18. Micro-computed tomography analysis of distal tibia metaphyses also revealed for the first time a major impact of the FVIII/thrombin/PAR1 axis on the dynamic bone structure, showing reduced bone.

  19. Findings indicate that improving protein trans-splicing by inter-chain disulfide bonding is a promising approach for increasing the efficacy of dual-vector based FVIII gene transfer.

  20. Acute elevations in FVIII levels result in a non-linear thrombogenic effect, with non-significant increases in thrombogenic risk. Prolonged elevation of plasma FVIII did not further increase the thrombogenic potential of elevated FVIII levels.

Human Coagulation Factor VIII (F8) interaction partners

  1. The K408 in the A2 domain of factor VIII provides an interactive-site for FX in the factor Xase complex.

  2. The impact of F8 mutations in non-severe hemophilia A patients on the protein structure and hence, diagnostic bioassay accuracy, has been evaluated.

  3. The type of F8 mutation is the main predictor of inhibitor development in patients with severe hemophilia A. Findings confirm an association between the synthesis of minute amounts of FVIII and inhibitor protection.

  4. the fraction of mosaic cells with an F8 promoter deletion may affect phenotype severity in a family with hemophilia A

  5. results provide novel insights on the adsorption and binding mechanism of the FVIII on cell membrane and will be helpful for the design of anticoagulant materials

  6. The D' domain of von Willebrand factor requires the presence of the D3 domain for optimal factor VIII binding.

  7. We demonstrated a high concordance in an appreciable number of siblings that developed inhibitors to FVIII or not. The presence of Inv22 and Inv1 in our population was associated to a moderate risk of developing inhibitors.

  8. Clustered F8 missense mutations cause hemophilia A by combined alteration of splicing and protein biosynthesis and activity

  9. Differential impacts of ectopic N-glycosylation on FVIII folding, trafficking and activity, which highlight complex disease-causing mechanisms of FVIII missense mutations.

  10. This study describes an original pathological mechanism by which a small intronic deletion in F8 leads to Alu exonization.

  11. A common polymorphism decreases LRP1 mRNA stability and is associated with increased plasma factor VIII levels

  12. F8 and F9 gene variants result from a founder effect in two large French haemophilia cohorts

  13. our results demonstrate that the N-glycosylation sequon in the A2 domain is located in a structural element that is critically required for proper folding and conformation of FVIII.

  14. The aim of this study was to determine the F8 mutations in severe HA (sHA) patients and female carriers

  15. Human FVIII gene transfer without in vivo selection of manipulated cells can introduce immune tolerance in hemophilia A mice and this immune tolerance is CD4(+) T cell mediated.

  16. In Factor VIII, 41 mutations were identified, 19 of which were novel and 80% (44/55) of the pathogenic mutations fell into the categories of missense, nonsense(16.36%), frameshift (14.55%), and splice (5.45%) mutations.

  17. High dose of rhFVIII induces apoptosis in FVIII-specific memory B-cells but does not influence FVIII-specific T cell response.

  18. the potential role of FXIII-A in wound healing, as a field with long-term therapeutic implications, is also discussed

  19. Case Report: complex recombination with deletion in the F8 and duplication in the TMLHE mediated by int22h copies during early embryogenesis in proband's mother.

  20. Report a diagnostic algorithm that can reliably identify pathogenic variants of factor 8/9 and von Willebrand factor and diagnose patients with hemophilia A, hemophilia B or von Willebrand disease.

Pig (Porcine) Coagulation Factor VIII (F8) interaction partners

  1. It was concluded that VEGF and factor VIII are important growth factors associated with fetal development in pigs and are identified in all uterine segments.

  2. Report Factor VIII organisation on nanodiscs with different lipid composition.

  3. thrombin stimulates transglutaminase activity in articular cartilage by directly cleaving factor XIII and by receptor-mediated up-regulation of factor XIII synthesis

  4. cupredoxin-like A1 subdomains in fVIII contain inter-species differences that are a result of selective pressure on the dissociation rate constant

Cow (Bovine) Coagulation Factor VIII (F8) interaction partners

  1. two factor VIII missense mutations are associated with a mild form of haemophilia A in German Fleckvieh cattle

  2. Factor VIIIc is responsible for tissue invasion during tumor progression.

  3. A missense mutation (p.Leu2153His) of the factor VIII gene causes cattle haemophilia A.

Factor VIII (F8) profil antigène

Profil protéine

This gene encodes coagulation factor VIII, which participates in the intrinsic pathway of blood coagulation\; factor VIII is a cofactor for factor IXa which, in the presence of Ca+2 and phospholipids, converts factor X to the activated form Xa. This gene produces two alternatively spliced transcripts. Transcript variant 1 encodes a large glycoprotein, isoform a, which circulates in plasma and associates with von Willebrand factor in a noncovalent complex. This protein undergoes multiple cleavage events. Transcript variant 2 encodes a putative small protein, isoform b, which consists primarily of the phospholipid binding domain of factor VIIIc. This binding domain is essential for coagulant activity. Defects in this gene results in hemophilia A, a common recessive X-linked coagulation disorder.

Gene names and symbols associated with F8

  • coagulation factor VIIi (f7i) anticorps
  • coagulation factor VIII (F8) anticorps
  • coagulation factor VIII, procoagulant component (F8) anticorps
  • AHF anticorps
  • Cf-8 anticorps
  • Cf8 anticorps
  • DXS1253E anticorps
  • F8B anticorps
  • F8C anticorps
  • fb61d02 anticorps
  • FVIII anticorps
  • HEMA anticorps
  • wu:fb61d02 anticorps

Protein level used designations for F8

Factor VIII , procoagulant component , antihemophilic factor , coagulation factor VIII , coagulation factor VIIIc , factor VIII F8B , coagulation factor VIII, procoagulant component (hemophilia A) , factor VIII , coagulation co-factor

GENE ID SPECIES
282671 Danio rerio
14069 Mus musculus
2157 Homo sapiens
397339 Sus scrofa
403875 Canis lupus familiaris
100271720 Bos taurus
100303761 Oryctolagus cuniculus
302470 Rattus norvegicus
100359363 Ovis aries
422199 Gallus gallus
Fournisseurs de qualité sélectionnés pour anti-Factor VIII (F8) Anticorps
Avez-vous cherché autre chose?